22 November 2022>: Original Paper
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
Gonzalo Sapisochin 1ADE** , Wei Chen Lee 2ABCDE , Dong Jin Joo 3ABD , Jae-Won Joh 4ABE , Koichiro Hata 56BCDE , Arvinder Singh Soin 7ACDE , Uday Kiran Veldandi 8ABCDEF , Shuhei Kaneko 9ACDE , Matthias Meier 10ACDEG , Denise Leclair 11DE , Gangadhar Sunkara 11CDEF , Long Bin Jeng 12AB**DOI: 10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
Table 4 Kaplan-Meier estimates of the proportion of subjects free from HCC recurrence (ITT).
Time since LT | EVR+rTAC N=56 | sTAC N=61 | ||||
---|---|---|---|---|---|---|
Cumulative incidence rate | KM% estimation without event | Cumulative incidence rate | KM% estimation without event | |||
n | KM% | (95% CI) | n | KM% | (95% CI) | |
Week 4* | 0 | 100.0 | (100.0, 100.0) | 0 | 100.0 | (100.0, 100.0) |
Month 12 | 0 | 100.0 | (100.0, 100.0) | 5 | 91.6 | (84.5, 98.6) |
Month 24 | 2 | 95.6 | (89.7, 100.0) | 6 | 89.8 | (82.0, 97.5) |
Month 36 | 2 | 95.6 | (89.7, 100.0) | 7 | 87.7 | (79.1, 96.3) |
Month 48 | 2 | 95.6 | (89.7, 100.0) | 7 | 87.7 | (79.1, 96.3) |
Month 60 | 2 | 95.6 | (89.7, 100.0) | 7 | 87.7 | (79.1, 96.3) |
* Day of randomization i.e., start point. CI – confidence interval; EVR – everolimus; HCC – hepatic cell carcinoma; ITT – intent-to-treat; KM – Kaplan-Meier; LT – liver transplantation; n – number of patients with event; N – the total number of patients in the treatment group; rTAC – reduced dose tacrolimus; sTAC – standard dose tacrolimus. |